Norgine to Present New Data at United European Gastroenterology Week 2015

LONDON, October 20, 2015 /PRNewswire/ --





Norgine B.V today announced that it will be presenting the following key data;


- European Colonoscopy Quality Investigation Group: Improving standards in
colonoscopy through a practice level audit tool. 26 October 2015, 12:00-13:30.
Poster 1245.[1]
- NER1006, a new low-volume bowel cleansing solution vs. trisulphate, polyethylene
glycol 3350+ascorbate or sodium picosulphate/magnesium salt: three ongoing multicentre
randomised parallel group phase III studies in 1914 patients undergoing colonoscopy
date. 27 October 2015, 11:00-12:30. Poster OP243.[2]
- Impact of switching from a brand to a generic macrogol on prescriptions and doses for
patients with chronic constipation in the UK. 27 October 2015, 12:30-13:30. Poster
1073.[3]
- Cost-effectiveness of Rifaximin-alpha (XIFAXAN(R)/TARGAXAN(R)) in the reduction of
recurrence of overt hepatic encephalopathy in United Kingdom. 28 October 2015,
11:00-12:30. Poster 1246.[4]
- Cost-effectiveness of Rifaximin-alpha (XIFAXAN(R)/TARGAXAN(R)) in the reduction of
recurrence of overt hepatic encephalopathy in Sweden. 28 October 2015, 11:00-12:30.
Poster 1245.[5]



     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )



1. European Colonoscopy Quality Investigation Group: Improving Standards in Colonoscopy Through a Practice Level Audit Tool. Abstract: UEG15-ABS-3692 

2. New Low-Volume Bowel Cleansing Solution (NER1006) vs Trisulphate, Polyethylene Glycol 3350+Ascorbate or Sodium Picosulphate/Magnesium Salt: Three Ongoing Multicentre Randomised Parallel Group Phase III Studies in 1914 Patients Undergoing Colonoscopy. Abstract: 15-ABS-3387 

3. Impact of Switching From a Brand to a Generic Macrogol on Prescriptions and Doses for Patients with Chronic Constipation in the UK. Abstract: UEG15-ABS-2167 

4. Cost Effectiveness of Rifaximin-alpha 550 mg (XIFAXAN/TARGAXAN) in the Reduction of Recurrence of Overt Hepatic Encephalopathy in United Kingdom. Abstract: UEG15-ABS-1973 

5. Cost Effectiveness of Rifaximin-alpha 550 mg (XIFAXAN/TARGAXAN) in the Reduction of Recurrence of Overt Hepatic Encephalopathy in Sweden. Abstract: UEG15-ABS-1961 

See full release on http://www.norgine.com

Contact:

Isabelle Jouin, T: +44(0)1895-453643

Charlotte Andrews, T: +44(0)1895-453607

Follow us @norgine



Photo:
http://photos.prnewswire.com/prnh/20130829/633895-a




Norgine B.V.

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234